Using the industry peer median P/E Multiples multiple (trailing + forward), 908 Devices Inc. (MASS) has a fair value of $20.90 based on 1 comparable companies in the Medical - Devices industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing P/E | Forward P/E | |
|---|---|---|---|
| 908 Devices Inc.MASS | 309 | 14.7x | — |
| SANUWAVE Health, Inc. | 147 | 41.7x | 17.7x |
| Industry Median | 41.7x | 17.7x | |
| (*) Profit after tax | 19 | ||
| Equity Value | 813 | ||
| (/) Outstanding shares | 39 | ||
| Fair Price | $21 | ||
Using the industry peer median EV/Revenue multiple (trailing + forward), 908 Devices Inc. (MASS) has a fair value of $8.75 based on 10 comparable companies in the Medical - Devices industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| 908 Devices Inc.MASS | 309 | 3.8x | 3.9x |
| Capricor Therapeutics, Inc. | 1,448 | 64.6x | 9.6x |
| NeuroPace, Inc. | 492 | 5.4x | 5.5x |
| Aclaris Therapeutics, Inc. | 458 | 56.3x | 97.4x |
| Cerus Corporation | 356 | 2.1x | 2.2x |
| Senseonics Holdings, Inc. | 279 | 7.9x | 4.7x |
| CVRx, Inc. | 238 | 3.8x | 3.8x |
| Sight Sciences, Inc. | 192 | 1.8x | 1.8x |
| Quanterix Corporation | 169 | 1.3x | 1.0x |
| Nano-X Imaging Ltd. | 151 | 10.6x | 9.0x |
| SANUWAVE Health, Inc. | 147 | 3.6x | 2.4x |
| Industry Median | 4.6x | 4.2x | |
| (*) Revenue | 56 | 55 | |
| = Enterprise Value | 258 | 231 | |
| (-) Net Debt | -96 | -96 | |
| Equity Value | 354 | 327 | |
| (/) Outstanding shares | 39 | 39 | |
| Fair Price | $9 | $8 | |
Using the PEG framework with historical EPS growth of 8.0%, the company has a fair value of $4.32 based on TTM EPS (FY2025) of $0.54.
| EPS Growth RateHistorical | 0.0% |
| Adjusted Growth (clamped 8–25%)Clamped | 8.0% |
| Fair P/E | 8.0x |
| TTM EPS (FY2025) | $0.54 |
| Fair Value | $4.32 |
No analyst estimates available.
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $-22.2M | $-0.79 | — |
| FY2022 | $-33.6M | $-1.07 | — |
| FY2023 | $-36.4M | $-1.13 | — |
| FY2024 | $-72.2M | $-2.12 | — |
| FY2025 | $19.5M | $0.54 | — |
4Y Historical EPS CAGR: 0.0%
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.